Paid Clinical Trials District of Columbia

Discover 802 paid clinical trials in District of Columbia. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 802

Study of ALXN2220 Versus Placebo in Adults With ATTR-CMStudy of ALXN2220 Versus Placebo in Adults With ATTR-CM

Recruiting

PHASE3

Sponsor:

Alexion Pharmaceuticals, Inc.

Location:

Washington DC, Falls Church VA, Richmond VA, Philadelphia PAshow 44 more

Code:

NCT06183931

Conditions

Transthyretin Amyloid Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ALXN2220

Placebo

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal AdenocarcinomaBXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

PHASE2

Sponsor:

Georgetown University

Location:

Washington DC, Hackensack NJ

Code:

NCT05558982

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BXCL701

Pembrolizumab

The QUALITY Vets Project: Muscle Quality and Kidney DiseaseThe QUALITY Vets Project: Muscle Quality and Kidney Disease

Recruiting

Sponsor:

Washington D.C. Veterans Affairs Medical Center

Location:

Washington DC, San Francisco CA

Code:

NCT03160326

Conditions

Chronic Kidney Disease

Sarcopenia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesTolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Recruiting

PHASE1

Sponsor:

Vanda Pharmaceuticals

Location:

Washington DC, Hackensack NJ, Lafayette IN, Fairway KSshow 1 more

Code:

NCT03838926

Conditions

Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trichostatin A

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting

PHASE3

Sponsor:

Bristol-Myers Squibb

Location:

Washington DC, Falls Church VA, Baltimore MD, Towson MDshow 87 more

Code:

NCT06003426

Conditions

Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

BMS-986278

BMS-986278 Placebo

A Study of EP0031 in Patients With Advanced RET-altered MalignanciesA Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting

PHASE1

PHASE2

Sponsor:

Ellipses Pharma

Location:

Washington DC, Fairfax VA, Philadelphia PA, New York NYshow 12 more

Code:

NCT05443126

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EP0031

A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Washington DC, Bethesda MD, Falls Church VA, Lanham MDshow 162 more

Code:

NCT05754957

Conditions

Acute Coronary Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Milvexian

Placebo

STOP-HER2: Stopping Trastuzumab in HER2+ MBCSTOP-HER2: Stopping Trastuzumab in HER2+ MBC

Recruiting

PHASE2

Sponsor:

Dana-Farber Cancer Institute

Location:

Washington DC, Pittsburgh PA, Durham NC, Milford MAshow 9 more

Code:

NCT05721248

Conditions

Breast Cancer

Metastatic Breast Cancer

HER2-positive Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cessation of anti-HER2 treatment

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

PHASE3

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Washington DC, Bethesda MD, Falls Church VA, Baltimore MDshow 45 more

Code:

NCT04045665

Conditions

Atrial Fibrillation

Stroke

Bleeding

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antiplatelet-only strategy

Oral Anticoagulant plus background antiplatelet therapy

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 InfectionNA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Recruiting

PHASE2

PHASE3

Sponsor:

Biomed Industries, Inc.

Location:

Washington DC, Bethesda MD, Baltimore MD, Philadelphia PAshow 26 more

Code:

NCT04452565

Conditions

Coronavirus Infection

Severe Acute Respiratory Infection

Severe Acute Respiratory Syndrome Coronavirus 2

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Drug: NA-831

NA-831 and Atazanavir

NA-831and Dexamethasone

Atazanavir and Dexamethasone

Popular cities in District of Columbia

Washington, D.C.